PMID- 17890443
OWN - NLM
STAT- MEDLINE
DCOM- 20071218
LR  - 20190722
IS  - 0009-9147 (Print)
IS  - 0009-9147 (Linking)
VI  - 53
IP  - 11
DP  - 2007 Nov
TI  - Influence of ScaI and natriuretic peptide (NP) clearance receptor polymorphisms 
      of the NP System on NP concentration in chronic heart failure.
PG  - 1886-90
AB  - BACKGROUND: Genetic variants related to the natriuretic peptide (NP) system [ScaI 
      mutated allele (A1) of the atrial NP (ANP) gene and the C variant of the 
      natriuretic peptide clearance receptor (NPRC) gene] have been identified as 
      independent risk factors for cardiovascular morbidity and mortality. Despite the 
      importance of NPs in heart failure (HF), the role of these polymorphisms in HF 
      has not been evaluated. METHODS: We screened 124 HF patients [mean (SD), age 66 
      (12) years, 100 men, ejection fraction 32% (10%), New York Heart Association 
      (NYHA) class I-II 65, III-IV 59] for NP concentrations [ANP, brain NP (BNP) and 
      amino-terminal pro-BNP (NT-proBNP)] and for the ScaI and NPRC variants. RESULTS: 
      ScaI polymorphism had no effect on NP concentration in the NYHA I-II subgroup. 
      Conversely, in severe HF, A1 carriers had higher ANP (P < or =0.05), BNP (P 
      <0.01), and NT-proBNP (P <0.01) than A2A2 patients. After multivariate 
      adjustment, A1 presence remained an independent predictor for increased NP. 
      Regarding NPRC polymorphism in mild HF, higher ANP (P <0.05) and BNP (P <0.05) 
      were observed in CC than A allele carriers. After multivariate adjustment, 
      however, this association did not remain significant. In severe HF, the NPRC 
      polymorphism had no effect on NP. CONCLUSIONS: The ScaI polymorphism of the ANP 
      gene might be an important additive genetic factor influencing neurohormonal 
      activation and disease progression in severe HF. The NPRC polymorphism is not an 
      independent determinant of NP concentration in HF.
FAU - Vassalle, Cristina
AU  - Vassalle C
AD  - Institute of Clinical Physiology, Consiglio Nazionale delle Ricerche, Pisa, 
      Italy. cristina.vassalle@ifc.cnr.it
FAU - Andreassi, Maria Grazia
AU  - Andreassi MG
FAU - Prontera, Concetta
AU  - Prontera C
FAU - Fontana, Marianna
AU  - Fontana M
FAU - Zyw, Luc
AU  - Zyw L
FAU - Passino, Claudio
AU  - Passino C
FAU - Emdin, Michele
AU  - Emdin M
LA  - eng
PT  - Journal Article
DEP - 20070921
PL  - England
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
RN  - EC 4.6.1.2 (Receptors, Atrial Natriuretic Factor)
RN  - EC 4.6.1.2 (atrial natriuretic factor receptor C)
SB  - IM
MH  - Aged
MH  - Atrial Natriuretic Factor/*genetics/metabolism
MH  - Female
MH  - Heart Failure/*genetics/metabolism
MH  - Humans
MH  - Male
MH  - Mutation
MH  - Natriuretic Peptide, Brain/*genetics/metabolism
MH  - Peptide Fragments/*genetics/metabolism
MH  - Polymorphism, Genetic
MH  - Receptors, Atrial Natriuretic Factor/*genetics
EDAT- 2007/09/25 09:00
MHDA- 2007/12/19 09:00
CRDT- 2007/09/25 09:00
PHST- 2007/09/25 09:00 [pubmed]
PHST- 2007/12/19 09:00 [medline]
PHST- 2007/09/25 09:00 [entrez]
AID - clinchem.2007.088302 [pii]
AID - 10.1373/clinchem.2007.088302 [doi]
PST - ppublish
SO  - Clin Chem. 2007 Nov;53(11):1886-90. doi: 10.1373/clinchem.2007.088302. Epub 2007 
      Sep 21.